RT Journal Article
SR Electronic
T1 Phenotypic evolution of SARS-CoV-2: a statistical inference approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.25.22279206
DO 10.1101/2022.08.25.22279206
A1 Benhamou, Wakinyan
A1 Lion, Sébastien
A1 Choquet, Rémi
A1 Gandon, Sylvain
YR 2023
UL http://medrxiv.org/content/early/2023/06/05/2022.08.25.22279206.abstract
AB Since its emergence in late 2019, the SARS-CoV-2 virus has spread globally, causing the ongoing COVID-19 pandemic. In the fall of 2020, the Alpha variant (lineage B.1.1.7) was detected in England and spread rapidly, outcompeting the previous lineage. Yet, very little is known about the underlying modifications of the infection process that can explain this selective advantage. Here, we try to quantify how the Alpha variant differed from its predecessor on two phenotypic traits: the transmission rate and the duration of infectiousness. To this end, we analysed the joint epidemiological and evolutionary dynamics as a function of the Stringency Index, a measure of the amount of Non-Pharmaceutical Interventions. Assuming that these control measures reduce contact rates and transmission, we developed a two-step approach based on SEIR models and the analysis of a combination of epidemiological and evolutionary information. First, we quantify the link between Stringency Index and the reduction in viral transmission. Secondly, based on a novel theoretical derivation of the selection gradient in an SEIR model, we infer the phenotype of the Alpha variant from its frequency changes. We show that its selective advantage is more likely to result from a higher transmission than from a longer infectious period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants ANR-16-CE35-0012 "STEEP" to SL and ANR-17-CE35-0012 "EVOMALWILD" to SG from the Agence Nationale de la Recherche. We also thank the MESRI (French Ministry of Research) and the Ecole Normale Superieure Paris-Saclay for the PhD scholarship of WB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Source data were openly available before the initiation of the study. Frequencies data were taken from the Public Health England (PHE) Technical Briefing 5, which was investigating the new VOC 202012/01 variant (Alpha) between September 2020 and January 2021: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957631/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_Data_England.ods; Daily epidemiological data from national screening in UK were downloaded from the website 'Our World in Data': https://ourworldindata.org/grapher/daily-tests-and-daily-new-confirmed-covid-cases?country=~GBR; Daily COVID-19-related deaths in UK were downloaded from the governmental website 'GOV.UK': https://coronavirus.data.gov.uk/details/deaths (see 'Daily deaths with COVID-19 on the death certificate by date of death'); eventually, the Stringency Index is computed by the Oxford COVID-19 Government Response Tracker: https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFrequencies data were taken from the Public Health England (PHE) Technical Briefing 5, which was investigating the new VOC 202012/01 variant (Alpha) between September 2020 and January 2021: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957631/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_Data_England.ods; daily epidemiological data from national screening in UK were downloaded from the website 'Our World in Data': https://ourworldindata.org/grapher/daily-tests-and-daily-new-confirmed-covid-cases?country=~GBR; daily COVID-19-related deaths in UK were downloaded from the governmental website 'GOV.UK': https://coronavirus.data.gov.uk/details/deaths (see 'Daily deaths with COVID-19 on the death certificate by date of death'); eventually, the Stringency Index is computed by the Oxford COVID-19 Government Response Tracker: https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/957631/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5_Data_England.ods https://coronavirus.data.gov.uk/details/death https://www.bsg.ox.ac.uk/research/research-projects/covid-19-government-response-tracker ACE2Angiotensin-Converting Enzyme 2CIConfidence IntervalCOVID-19COronaVIrus Disease-2019i.i.d.independent and identically distributedMEMMixed-Effects ModelNHSNational Health Service (UK)NPINon-Pharmaceutical InterventionODEOrdinary Differential EquationORF1abOpen Reading Frames 1a and 1bOxCGRTOxford COVID-19 Government Response TrackerPHEPublic Health England (now replaced by UKHSA)qPCRquantitative Polymerase Chain ReactionSSpike (viral gene and protein)SARS-CoV-2Severe Acute Respiratory Syndrome-CoronaVirus-2S(E)IRSusceptible-(Exposed-)Infectious-RecoveredSGTFS Gene Target FailureVOCVariant Of ConcernWHOWorld Health OrganizationWLSWeighted Least SquaresWTWild Type